us en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure Show More Show Less Compare false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $116.28

    as of October 20, 2026
  • YTD RETURNS
    14.71%

    as of October 20, 2026
  • Total Net Assets
    $1.13B

    as of October 20, 2026
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

Overview

Why PPH

  • Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
  • Industry LeadersFavors established industry leaders with meaningful scale
  • Global ScopeProvides exposure to U.S. and international equities for global industry representation

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Performance

Average Annual Total Returns* (%)

  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) -3.28 0.50 7.51 23.60 13.35 10.67 8.69 10.00
PPH (Market Price) -3.19 0.67 7.58 23.72 13.37 10.65 8.70 10.09
MVIS US Listed Pharmaceutical 25 Index -3.26 0.55 7.32 23.42 13.00 10.31 8.44 9.81
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) -3.28 0.50 7.51 23.60 13.35 10.67 8.69 10.00
PPH (Market Price) -3.19 0.67 7.58 23.72 13.37 10.65 8.70 10.09
MVIS US Listed Pharmaceutical 25 Index -3.26 0.55 7.32 23.42 13.00 10.31 8.44 9.81

Holdings

Daily Holdings (%) as of 10/20/2026

Download XLS Get holdings
Total Holdings: 26
Ticker
Holding Name
% of Net Assets
Market Value (US$)
LLY
Eli Lilly & Co
21.60
233,244,873
MRK
Merck & Co Inc
12.79
138,109,269
NVO
Novo Nordisk A/S
5.47
59,058,487
PFE
Pfizer Inc
5.12
55,350,671
MCK
Mckesson Corp
4.92
53,098,566
TEVA
Teva Pharmaceutical Industries Ltd
4.61
49,812,082
BMY
Bristol-Myers Squibb Co
4.53
48,903,111
COR
Cencora Inc
4.52
48,796,174
GSK
Gsk Plc
4.43
47,850,869
HLN
Haleon Plc
3.92
42,372,674
ABBV
Abbvie Inc
3.77
40,714,027
NVS
Novartis Ag
3.66
39,492,855
AZN
Astrazeneca Plc
3.52
38,014,212
JNJ
Johnson & Johnson
3.18
34,316,959
SNY
Sanofi Sa/France
3.16
34,142,290
TAK
Takeda Pharmaceutical Co Ltd
2.82
30,410,156
ZTS
Zoetis Inc
2.66
28,779,983
VTRS
Viatris Inc
1.49
16,044,856
JAZZ
Jazz Pharmaceuticals Plc
1.15
12,380,765
CORT
Corcept Therapeutics Inc
0.73
7,903,694
AXSM
Axsome Therapeutics Inc
0.60
6,444,479
ELAN
Elanco Animal Health Inc
0.47
5,121,937
DFTX
Definium Therapeutics Inc
0.42
4,570,437
OGN
Organon & Co
0.27
2,945,479
PRGO
Perrigo Co Plc
0.11
1,186,377
-USD CASH-
--
0.00
10,708
--
Other/Cash
0.09
985,385
← Scroll for more information →
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Portfolio

Sector Weightings (%) as at 09/30/2026

  • Sector

    % of Net Assets
  • Health Care

    99.62
  • Other/Cash

    0.38

Country Weightings (%) as at 09/30/2026

  • Country

    % of Net Assets
  • United States

    67.84
  • United Kingdom

    11.75
  • Denmark

    5.60
  • Israel

    4.75
  • Switzerland

    3.61
  • France

    3.35
  • Japan

    2.71
  • Other/Cash

    0.38

Fees

Distributions

  as of  10/21/2026


Distribution Frequency

Quarterly


30-Day SEC Yield

1.68%


Distribution Yield

1.25%


12 Month Yield

1.85%

Yield information reflects temporary waivers of expenses and/or fees. Yields would have been reduced had these fees/expenses been included. In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Pharmaceutical ETF would have been 1.68% on 10/21/26. Distributions may vary from time to time.

Team

Resources

PPH